News

REGISTRATION OF THE WARRANTS TO6 - SHAREHOLDERS RECEIVE WARRANTS AT NO CONSIDERATION

On November 9, 2018, MediRätt announced that the company had called upon a second tranche of convertibles under the agreement on financing through issuance of convertibles entered into with European Select Growth Opportunities Fund (the "Investor"). MediRätt also informed that the company had decided to, at no consideration, issue 430,851 warrants TO6 to the Investor and 426,692 warrants to iZafe AB (formerly Sensec Personlig Säkerhet AB, currently under name change) with the right and obligation to transfer its warrants at no consideration to the shareholders in MediRätt pro rata in proportion to the number of shares in MediRätt they hold at the date five trading days after the date of registration of the issue resolution at the Swedish Companies Registration Office.

The convertible and the warrants have been registered at the Swedish Companies Registration Office on November 29, 2018. Shareholders will therefore, at no consideration, receive warrants pro rata in proportion to the number of shares they own as of December 7, 2018. An application to list the warrants for trading on Nasdaq First North Premier will be submitted to Nasdaq Stockholm. The estimated first day of trading will be announced once such date has been set.

The terms in brief:

  • The right to subscribe for 430,851 warrants shall vest in European Select Growth Opportunities Fund. The right to subscribe the remaining 426,692 warrants shall vest in iZafe AB. iZafe AB shall have the right and obligation to transfer its warrants at no consideration to the shareholders in MediRätt AB pro rata in proportion to the number of shares in MediRätt AB they hold at the date five trading days after the date of registration of the issue resolution at the Swedish Companies Registration Office. The reason for not applying the shareholders' pre-emption rights is to strengthen the liquidity and financial position of the company pursuant to an agreement entered into with European Select Growth Opportunities Fund.
  • The warrants shall be issued at no consideration.
  • Subscription for the warrants shall take place within three weeks of the date of the resolution to issue warrants.
  • The board of directors shall be entitled to extend the subscription period.
  • Simultaneous exercise of less than 53,192 Warrants may take place on six occasions during the two-week period preceding the day of 6, 12, 18, 24, 30 and 36 months after the date on which the Warrants are registered at the Swedish Companies Registration Office. The company will publicly announce the dates for the subscription period. Simultaneous exercise of 53,192 or more Warrants may take place during the period commencing on the date on which the first Warrants are registered at the Swedish Companies Registration Office up to and including the day three (3) years after the date of registration of the first Warrants issued with the Swedish Companies Registration Office.

Due to an increase in the number of shares in MediRätt, from 13,738,190 shares as of the date of the resolution to issue the warrants, to 14,538,586 shares as of the date of this press release, the number of shares required to be entitled to receive one warrant has increased, from 31 shares to 35 shares.

For detailed terms of the warrants, please visit: http://www.mediratt.com/en/investor-relations/financing-from-l1-capital/ 

Stockholm 2018-11-30

Contact CEO Carl Johan Merner:
carl.johan.merner@mediratt.com

This information is such that MediRätt AB (publ) is obligated to disclose in accordance with the EU Market Abuse Regulation (MAR). The information was submitted for publication on November 30, 2018 at 5.45 pm CET.

MediRätt AB (publ)
Stockholmsvägen 33
181 33 Lidingö

+ 46 (0)8 765 66 33
info@mediratt.com
mediratt.com

About MediRätt AB (publ)

MediRätt is a Swedish medical technology company that develops digital solutions for safer medication and drug dispensing. The company was founded in 2008 by general physician Göran Sjönell and industrialist Sten Röing. MediRätt has developed the patented digital drug dispensing machine Dosell, as well as a series of applications that together form a unique overall concept to ensure that elderly and multi-medicating patients receive reliable and safe medication.

The company is listed on NASDAQ First North Premier. Erik Penser Bank, +46 (0)8 463 80 00, is the company's Certified Adviser. Further information is available at mediratt.com

March 8, 2019
Regulatory

The shareholders of MediRätt AB, 556762-3391 (the "Company") are hereby invited to the Annual General Meeting on Wednesday, 10 April 2019 at 2:00 p.m. at Priority, Skeppsbron 24, Stockholm, Sweden

February 15, 2019
Regulatory

On 14 February 2019, MediRätt announced that Svensk Konstruktionstjänst AB ("SveKon"), developer of the Dosell system, invests SEK 3 million in MediRätt through a directed issue of new shares. The board of directors of MediRätt today resolved, by power of authorisation from the annual general meeting held on 11 April 2018, on a directed issue of 528,169 new series B shares to SveKon against payment through set-off of a claim valued at SEK 3 million.

November 30, 2018
Regulatory

On November 9, 2018, MediRätt announced that the company had called upon a second tranche of convertibles under the agreement on financing through issuance of convertibles entered into with European Select Growth Opportunities Fund (the "Investor"). MediRätt also informed that the company had decided to, at no consideration, issue 430,851 warrants TO6 to the Investor and 426,692 warrants to iZafe AB (formerly Sensec Personlig Säkerhet AB, currently under name change) with the right and obligation to transfer its warrants at no consideration to the shareholders in MediRätt pro rata in proportion to the number of shares in MediRätt they hold at the date five trading days after the date of registration of the issue resolution at the Swedish Companies Registration Office.

November 20, 2018
Regulatory

The shareholders of MediRätt AB, 556762-3391, (the "Company") are hereby invited to an Extraordinary General Meeting on Tuesday, 18 December 2018 at 14.00, at Priority, Skeppsbron 24, Stockholm, Sweden.

November 9, 2018
Regulatory

On May 21, 2018, MediRätt and European Select Growth Opportunities Fund (the "Investor") signed an agreement under which MediRätt may issue convertible bonds in several tranches for a total maximum amount of SEK 50 million over 18 months. A first tranche of SEK 2.5 million has been issued on June 13, under which all the convertibles have been converted into shares as of today, strengthening the company's equity.

October 30, 2018

Today, MediRätt's subsidiary signed an agreement with Borlänge municipality after winning a direct procurement for courses in security training. Under the agreement, Sensec will train Borlänge municipality staff on 10 to 15 occasions in three different areas: threats and violence in the workplace, ongoing deadly violence, and emergency preparedness.

October 25, 2018

In conjunction with MediRätt's Q3 report, Erik Penser Bank today published a follow-up analysis of the company. Against a background of higher than expected sales for Q3, the bank has revised upwards its EBIT estimate by SEK 1.8 million for 2018.

October 24, 2018
Regulatory

THIRD QUARTER IN BRIEF
GROUP

SALES:
2,704 SEK 000s (0 SEK 000s)

PROFIT AFTER TAX:
-2,101 SEK 000s (-1,100 SEK 000s)

PROFIT PER SHARE BEFORE DILLUTION:
-0.2 SEK (-0.1 SEK)

NUMBER OF SHARES AS AT 30 JUNE:
13,566,762 (11,692,028)

October 15, 2018

Today, MediRätt has signed a pilot project agreement for Dosell with Uppsala municipality. The trial will be conducted for a period of six months with the option of an extension. If the test is successful, Uppsala municipality may decide to purchase Dosell through a public procurement process.

October 15, 2018

The process to obtain CE marking for Dosell as a MDD Class 1 medtech product continues as planned. MediRätt is expecting that the process can be completed during week 48.

1
2
3
4
5
6

Prenumerera

Pressmeddelanden och rapporter via E-post.